NCT04642261View on ClinicalTrials.gov

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

June 30, 2023

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

Empagliflozin 10 MG

Empagliflozin 10mg daily

DRUG

Placebo pills

Identical in appearance to empagliflozin 10mg daily

Trial Locations (1)

852

The University of Hong Kong/Queen Mary Hospital, Hong Kong

All Listed Sponsors
collaborator

Food and Health Bureau, Hong Kong

OTHER_GOV

lead

The University of Hong Kong

OTHER

NCT04642261 - Effect of Empagliflozin on Liver Fat in Non-diabetic Patients | Biotech Hunter | Biotech Hunter